Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the week of 31st Aug - 07th Sep PharmaEssentia ( FDA, Approval ) FDA approves PharmaEssentia's BESREMi to treat adults with Essential Thrombocythemia, regardless of genotype or disease status Ionis ( FDA, Approval ) Ionis' ZANVASTRO gets FDA approval to treat Alexander disease in pediatric and adults patients AstraZeneca ( FDA, Approval ) FDA provides approval to AstraZeneca's ETCAMAH, in combination with CDK 4/6 inhibitor, to treat adults with HR-positive, HER2- negative, locally advanced or metastatic breast cancer AstraZeneca ( EU, Approval ) AstraZeneca's ENHERTU, in combination with pertuzumab, gets EU approval to treat adults with unresectable or metastatic HER2-positive breast cancer All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 31st August – 07th September in the world of pharma and healthcare!

September 7, 2026

Highlights from the Week of 24th August 2026 - 31st August 2026 ( US, Launch ) Cycle Pharma launches CAVHANZA in the US to offer dosing flexibility and tolerability for patients with Ph+ CML ( EU, Launch ) Celltrion launches OMLYCLO 300 mg PFS and AI presentations in key European markets for CSU and allergic asthma ( FDA, Approval ) J&J receives approval from the FDA for IMAAVY to treat wAIHA in patients aged 12 and older ( FDA, Approval ) Jazz Pharmaceuticals gets FDA approval for ZIIHERA regimens to treat adults with unresectable locally advanced or metastatic HER2+ gastroesophageal adenocarcinoma Pg 1/5 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 24th August – 31st August in the world of pharma and healthcare!

August 31, 2026

Highlights from the week of 17th Aug - 24th Aug Biocon ( FDA, Approval ) Biocon receives approval from FDA for YESINTEK 45 mg/0.5 mL and 90 mg/mL single-dose prefilled autoinjectors to treat adult and pediatrics with psoriasis, and adults with CD and UC Regeneron ( FDA, Approval ) Regeneron gets FDA approval for PASATRU, indicated to reduce the formation of new HO lesions and clinician-assessed flare-ups in adults with FOP Ultragenyx ( FDA, Accelerated Approval ) FDA grants accelerated approval for Ultragenyx's DTX401, indicated to treat GSDIa in adults and pediatrics Johnson&Johnson ( EU, Approval ) J&J receives indication extension approval from EC for TECVAYLI in combination with daratumumab to treat adults with RRMM who received at least one prior therapy All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 17th August – 24th August in the world of pharma and healthcare!

August 24, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

2026 RBC Capital Markets Global Healthcare Conference Bank of America Global Healthcare Conference Sep 22,2026 To Sep 23,2026 Sep 23 Sep 22 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of Sep 22,2026 To Sep 23,2026

September 21, 2026

2026 RBC Capital Markets Global Healthcare Conference Morgan Stanley 24th Annual Global Healthcare Conference Sep 14,2026 To Sep 15,2026 Sep 15 Sep 14 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 14,2026 To September 15,2026

September 14, 2026

2026 RBC Capital Markets Global Healthcare Conference Wells Fargo 21st Annual Healthcare Conference Sep 09,2026 To Sep 10,2026 Sep 10 Sep 09 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 09,2026 To September 10,2026

September 7, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

WORLD Schizophrenia Day 2026 Definition Schizophrenia is a serious mental illness that affects how a person thinks, feels, and behaves Global Prevalence US Prevalence 1.22 M 23.6 M People live with Schizophrenia worldwide New cases are diagnosed globally each year Prevalence of schizophrenia & related psychotic disorders 0.25% & 0.64% Late adolescence and the twenties, Earlier among men than among women 0% 0.1% 0.2% 0.3% 0.4% 0.5% Types of Schizophrenia Paranoid delusions focusing on the self Belief in being targeted by people, objects 'others'. Excitement & stupor phases Reluctance to move limbs/body Symptoms that don't clearly fit one of the other types Bizarre behavior, delusions & hallucinations Often occurs in adolescence Paranoid Catatonic Disorganized Undifferentiated Symptoms Positive Symptoms : any change in behaviour or thoughts Negative symptoms : often appear months or years before a person experiences delusions or hallucinations Positive Symptoms Delusions Confused thinking and speech Hallucinations Negative Symptoms Lack of Motivation Social Withdrawal Emotional Flatness Cognitive Symptoms Attention issues Problem-solving Impaired verbal ability Diagnosis > 2 of the specified symptoms according to DSM-5 classification for a duration of 1 month Recent update Clinical Interview for DSM-5 (SCID) How long symptoms have been appearing Rule out other possible illnesses Rule out substance use SNPs may now serve as biomarkers Treatment 1st Generation 2nd Generation New MOA MOA Typical mGPCR antagonists Atypical mGPCR antagonists M1/M4 agonist Drug Name Company Name Drug Name Company Name Drug Name Company Name Drugs Haloperidol Clozapine COBENFY Chlorpromazine Olanzapine Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

Today, we recognize Bipolar Disorder and Schizophrenia Awareness and stand in support of individuals, families, and communities affected by these conditions. By encouraging understanding, empathy, and open conversations, we can help reduce stigma and promote mental well-being for all.

May 24, 2026

INFLAMMATORY BOWEL DISE SE IBD is an umbrella term for a group of conditions that cause swelling and inflammation of the tissues in the digestive tract Global Prevalence and Incidence Country-wise affected population Prevalence 2.4-3.1M 229.7 per 100,000 2.5-3 M Incidence Low Low with increase 0.18 M High TYPES OF IBD Crohn's disease Ulcerative colitis Crohn's disease (CD): It can affect any part of the digestive tract from mouth to anus and causes deep, tissue-layer inflammation Ulcerative colitis (UC): It affects only the colon and rectum's inner lining, causing inflammation and ulcers DIAGNOSIS Blood Test Stool Test Upper Endoscopy Colonoscopy Tissue Biopsy Imaging Studies Risk factors Causes of inflammatory Bowel Disease Medium Women face a higher risk of CD; men face a higher risk of UC Smoking affects development and severity of Crohn's Commonly diagnosed between ages 15-35 Luminal Factors Microbiome Intestinal Immune System Alterations Environmental Factor Genetic Predisposition SYMPTOMS Loss of appetite Fatigue Stomach aches and cramps Weight loss Diarrhea Blood in your stool TREATMENT Surgery Bowel resection Top-down approach Nutritional support Probiotics Biologic therapy Adalimumab & Infliximab Immunosuppressants Methotrexate, Azathioprine & Mercaptopurine Corticosteroids Budesonide, Methylprednisolone & Prednisolone 5-ASA | Antibiotics 5 ASA- Mesalamine & Sulfasalazine | Antibiotics- Ciprofloxacin & Metronidazole Step-up approach Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜

May 19, 2026

High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️

May 17, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of Use

Privacy Policy

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message